About Abionic
Abionic is a company based in Epalinges (Switzerland) founded in 2010 by Iwan Märki and Nicolas Durand.. Abionic has raised $28.94 million across 4 funding rounds from investors including Zurcher Kantonalbank, Pierangelo Bottinelli and Philippe Glatz. Abionic offers products and services including abioSCOPE and PSP Assay. Abionic operates in a competitive market with competitors including OpGen, CytoVale, SphingoTec, Avails Medical and Qvella Corporation, among others.
- Headquarter Epalinges, Switzerland
- Founders Iwan Märki, Nicolas Durand
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$28.94 M (USD)
in 4 rounds
-
Latest Funding Round
$21.13 M (USD), Series C
Mar 28, 2018
-
Investors
Zurcher Kantonalbank
& 14 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Abionic
Abionic offers a comprehensive portfolio of products and services, including abioSCOPE and PSP Assay. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Rapid tool for sepsis detection from blood samples in minutes.
Test to detect sepsis risk using Pancreatic Stone Protein.
Unlock access to complete
Unlock access to complete
Funding Insights of Abionic
Abionic has successfully raised a total of $28.94M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $21.13 million completed in March 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series C — $21.1M
-
First Round
First Round
(04 Oct 2010)
- Investors Count 15
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2018 | Amount | Series C - Abionic | Valuation | Pierangelo Bottinelli | |
| Oct, 2014 | Amount | Series B - Abionic | Valuation |
investors |
|
| Apr, 2012 | Amount | Series A - Abionic | Valuation | MedHoldings |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Abionic
Abionic has secured backing from 15 investors, including angel, institutional, and venture fund investors. Prominent investors backing the company include Zurcher Kantonalbank, Pierangelo Bottinelli and Philippe Glatz. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on science and tech-driven startups
|
Founded Year | Domain | Location | |
|
Investment in early-stage medical device and life science companies with network support.
|
Founded Year | Domain | Location | |
|
Business Angels Switzerland is focused on investing in innovative startups.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Abionic
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Abionic
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Abionic Comparisons
Competitors of Abionic
Abionic operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as OpGen, CytoVale, SphingoTec, Avails Medical and Qvella Corporation, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of diagnostics and bioinformatics platforms for providers
|
|
| domain | founded_year | HQ Location |
Microfluidic-based biomarkers for the early detection of sepsis
|
|
| domain | founded_year | HQ Location |
Biomarker-based diagnostic solutions for cancer and cardiovascular diseases are developed.
|
|
| domain | founded_year | HQ Location |
Point-of-care devices are developed for infection diagnosis and treatment optimization.
|
|
| domain | founded_year | HQ Location |
Develops innovative platforms for accurate and rapid bacteria diagnosis in healthcare.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Abionic
Frequently Asked Questions about Abionic
When was Abionic founded?
Abionic was founded in 2010.
Where is Abionic located?
Abionic is headquartered in Epalinges, Switzerland. It is registered at Epalinges, Vaud, Switzerland.
Who is the current CEO of Abionic?
Patrick Pestalozzi is the current CEO of Abionic.
Is Abionic a funded company?
Abionic is a funded company, having raised a total of $28.94M across 4 funding rounds to date. The company's 1st funding round was a Series A of $3.7M, raised on Oct 04, 2010.
What does Abionic do?
Abionic was founded in 2010 and is based in Epalinges, Switzerland. Diagnostic tools for allergies are developed by the company within the healthcare sector. Operations focus on point-of-care solutions, including the abioSCOPE device for measuring IgE concentrations from blood samples, the abioGUIDE application for report viewing on mobile devices, and screening capsules that assess respiratory allergies using minimal blood volume.
Who are the top competitors of Abionic?
Abionic's top competitors include CytoVale, Avails Medical and SphingoTec.
What products or services does Abionic offer?
Abionic offers abioSCOPE and PSP Assay.
Who are Abionic's investors?
Abionic has 15 investors. Key investors include Zurcher Kantonalbank, Pierangelo Bottinelli, Philippe Glatz, Arkady Volozh, and Peter Brabeck-Letmathe.